Commentary|Articles|June 23, 2026

ADA 2026: Obesity Pharmacotherapy and the Future of Weight Management

Author(s)Jennifer Goldman, PharmD, RPh, CDCES, BC-ADM, FCCP

Fact checked by: Gillian McGovern, Editor

Understanding this rapidly evolving therapeutic landscape will be essential as obesity pharmacotherapy continues to transform diabetes and cardiometabolic care.

If there was one therapeutic area that generated excitement throughout the 86th American Diabetes Association (ADA) Scientific Sessions, it was obesity pharmacotherapy. While glucagon-like peptide (GLP)-1 receptor agonists transformed obesity treatment over the past several years, ADA 2026 provided a glimpse into what may come next: triple agonists, amylin analogues, dual GLP-1/glucagon therapies, and next-generation combination approaches capable of producing unprecedented weight loss while improving glycemic control and cardiometabolic health.